A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab

European Journal of Dermatology

Volumn 27, Issue 2, 2017, Pages 193-194

  Oishi, Kyosuke ^a   Nakao, Masaharu ^a   Maeda, Shintaro ^a   Matsushita, Takashi ^a   Ikeda, Tokuhei ^a   Yamada, Tadaaki ^a   Takehara, Kazuhiko ^a   Hamaguchi, Yasuhito ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DACARBAZINE; IPILIMUMAB; METHYLPREDNISOLONE; PREDNISOLONE; PROCALCITONIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NEUROPROTECTIVE AGENT;

ADULT; ASEPTIC MENINGITIS; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; FEVER; HEADACHE; HUMAN; HUMAN TISSUE; LETTER; LEUKOCYTE COUNT; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPHADENOPATHY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; STIFF NECK; VOMITING; CHEMICALLY INDUCED; HEAD AND NECK TUMOR; MELANOMA; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; HEAD AND NECK NEOPLASMS; HUMANS; IPILIMUMAB; MALE; MELANOMA; MENINGITIS, ASEPTIC; METHYLPREDNISOLONE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; SKIN NEOPLASMS;

EID: 85017602266     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2016.2943     Document Type: Letter

References (6)

1. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825-30.
2. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8: e53745.
3. Stein MK, Summers BB, Wong CA, Box HL, Cleveland KO. Meningoencephalitis following ipilimumab administration in metastatic melanoma. Am J Med Sci 2015; 350: 512-3.
4. Moris G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis revisited. JAMA Intern Med 2014; 174: 1511-2.
5. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immunerelated adverse events of ipilimumab. Pract Neurol 2013; 13: 278-80.
6. Bompaire F, Mateus C, Taillia H, et al. Severe meningoradiculo-neuritis associated with ipilimumab. Invest New Drugs 2012; 30: 2407-10.